TP53 and breast carcinoma: The effect on breast cancer risk of the TP53 Arg72Pro and the MDM2 309T>G polymorphisms, separately and in combination, was investigated in a large case–control study by the Breast Cancer Association Consortium (BCAC), but no association was detected (Schmidt et al, 2007).